Logos Global Management LP - 21 Jun 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Reporting relationship: 10%+ Owner
Issuer ticker: VERV
Reported as of: 21 Jun 2021
Net transaction value: +$7,030,000
SEC form: 4
Accepted by SEC: 22 Jun 2021, 17:21:53 UTC
Prior SEC filing: 16 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/Arsani William, Managing Partner

Key filing fact

Logos Global Management LP filed Form 4 for Verve Therapeutics, Inc. (VERV) on 22 Jun 2021.

Key facts

This page summarizes Logos Global Management LP's Form 4 filing for Verve Therapeutics, Inc. (VERV).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Jun 2021, 17:21.

Change

Previous filing in this sequence was filed on 16 Jun 2021.
Current net transaction value: +$7,030,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VERV transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +443,265
Change %
Price
Shares after: 443,265
Date: 21 Jun 2021
Ownership: See Footnotes
Footnotes: F1, F2, F3

VERV transaction

Common Stock

Purchase

Transaction value: $7,030,000
Shares: +370,000
Change %
Price: $19.00
Shares after: 370,000
Date: 21 Jun 2021
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VERV transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -4,104,416
Change %: -100%
Price
Shares after: 0
Date: 21 Jun 2021
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 443,265
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Logos Global Management LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.

Footnote F2

The reporting persons are Logos Opportunities Fund II, LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William is the controlling person of LGM and Logos GP and Dr. William and Dr. Walmsley are the managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.

Footnote F3

The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William as controlling person of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.